El interés en corto de Creative Medical Tech da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Creative Medical Tech. Los datos de interés en corto se actualizan cada dos semanas.

Creative Medical Tech (NASDAQ:CELZ) Bolsa, Informe de interés en corto

Creative Medical Tech

Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Technology Holdings Inc

TD Cowen analyst Lance Vitanza maintains Caesars Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) with a Buy and lowers the price target from $50 to $48.

News

Price Target

Analyst Ratings

TD Cowen Maintains Buy on Caesars Entertainment, Lowers Price Target to $48

Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) reported better-than-expected second-quarter financial <a href="https://www.benzinga.com/quote/CAH/earnings">results on Thursday</a>.
Cardinal Health posted adjusted earnings of $1.93 per share, beating market estimates of $1.76 per share. The company posted sales of $55.3 billion, topping expectations of $54.915 billion.
&#8220;We delivered strong second quarter financial results while taking significant strategic and operational actions to position us for future growth,&#8221; said Jason Hollar, CEO of Cardinal Health. &#8220;Led by robust demand across our Pharmaceutical and Specialty Solutions segment, we are again pleased to raise our fiscal 2025 enterprise guidance.&#8221;
Cardinal Health raised its FY25 non-GAAP earnings guidance from $7.75-$7.90 per share to $7.85-$8.00 per share.
Cardinal Health shares gained 1.3% to trade at $126.92 on Tuesday.
These analysts made changes to their price targets on Cardinal Health following earnings announcement.
<ul>
<li>Wells Fargo analyst Stephen Baxter maintained Cardinal Health with an Equal-Weight and raised the price target from $135 to $136.</li>
<li>JP Morgan analyst Lisa Gill maintained Cardinal Health with a Neutral and raised the price target from $142 to $145.</li>
</ul>
Considering buying CAH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133226/image-2-5-1024x575.png" alt="" class="wp-image-765459" style="width:609px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133226/image-2-5-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133226/image-2-5-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133226/image-2-5-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133226/image-2-5.png 1116w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43463896/mcdonalds-to-290-here-are-10-top-analyst-forecasts-for-tuesday">McDonald&#8217;s To $290? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Earnings

Markets

Trading Ideas

Cardinal Health Analysts Raise Their Forecasts Following Upbeat Earnings

TD Cowen analyst Lance Vitanza downgrades NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) from Buy to Hold and lowers the price target from $46 to $27.

Downgrades

NSSC

TD Cowen Downgrades NAPCO Security Techs to Hold, Lowers Price Target to $27

On Tuesday, Cumberland Pharmaceuticals Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) released topline results from its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43459112/cumberland-pharmaceuticals-announces-breakthrough-results-from-the-phase-2-fight-dmd-trial-in-duch" rel="noreferrer noopener">Phase 2 FIGHT DMD trial</a>.
The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of <a target="_blank" href="https://www.benzinga.com/quote/CPIX" rel="noreferrer noopener">death in DMD patients</a>.
DMD is a rare and incurable pediatric disease caused by mutations in the gene encoding dystrophin, a protein critical for muscle function, including the heart.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42419338/why-is-cumberland-pharmaceuticals-stock-trading-over-100-on-tuesday" rel="noreferrer noopener">Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?</a>
Patients with DMD slowly lose muscle function, resulting in the inability to walk, difficulty breathing, and heart failure.
The trial enrolled 41 patients who received either low-dose ifetroban (150 mg per day), high-dose ifetroban (300 mg per day), or placebo.
The study&#8217;s primary endpoint was an improvement in the heart&#8217;s left ventricular ejection fractions (LVEF), a key indicator of how well the heart is pumping blood.&nbsp;
Key findings include:
<ul>
<li>High-dose ifetroban treatment resulted in an overall 3.3% improvement in LVEF.</li>
<li>The high-dose ifetroban group showed an increase in 1.8% in LVEF, while the study placebo group showed an expected decline in LVEF of 1.5%</li>
<li>The difference was even more pronounced when compared with propensity-matched natural history controls, with the high-dose treatment providing a significant 5.4% overall improvement in LVEF, while the control patients experienced a 3.6% decline.</li>
<li>Both doses of ifetroban were well-tolerated, with no serious drug-related events.</li>
</ul>
Ifetroban has received both&nbsp;Orphan Drug Designation&nbsp;and&nbsp;Rare Pediatric Disease Designation&nbsp;from the FDA. If approved, ifetroban would be the first therapy specifically indicated for DMD-related heart disease.
Price Action: CPIX stock is up 23.01% at $2.62 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43459558/novo-nordisk-faces-investor-concerns-over-hybrid-cagrisema-trial-results-for-weight-loss" target="_blank" rel="noreferrer noopener">Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss</a></li>
</ul>

Biotech

Health Care

Movers

General

CPIX

Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

HSBC analyst Edoardo Spina downgrades Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) from Buy to Hold and lowers the price target from $109 to $100.

HSBC Downgrades Autoliv to Hold, Lowers Price Target to $100

Deep-pocketed investors have adopted a bearish approach towards Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AAPL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 80 extraordinary options activities for Apple. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 43% bearish. Among these notable options, 18 are puts, totaling $2,635,916, and 62 are calls, amounting to $3,937,782.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $285.0 for Apple during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Apple's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Apple's whale trades within a strike price range from $100.0 to $285.0 in the last 30 days. 
<h3>Apple 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738693833_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAPL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$227.50</td>
<td>$1.8M</td>
<td>2.0K</td>
<td>6.7K</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$135.5</td>
<td>$134.7</td>
<td>$135.13</td>
<td>$100.00</td>
<td>$270.2K</td>
<td>1.1K</td>
<td>30</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$13.1</td>
<td>$12.9</td>
<td>$13.1</td>
<td>$260.00</td>
<td>$262.0K</td>
<td>14.4K</td>
<td>221</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$8.75</td>
<td>$8.6</td>
<td>$8.73</td>
<td>$275.00</td>
<td>$240.9K</td>
<td>6.6K</td>
<td>281</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$134.95</td>
<td>$134.25</td>
<td>$134.67</td>
<td>$100.00</td>
<td>$188.5K</td>
<td>1.1K</td>
<td>74</td>
</tr>
</tbody>
</table>

<h3>About Apple</h3>
Apple is among the largest companies in the world, with a broad portfolio of hardware and software products targeted at consumers and businesses. Apple's iPhone makes up a majority of the firm sales, and Apple's other products like Mac, iPad, and Watch are designed around the iPhone as the focal point of an expansive software ecosystem. Apple has progressively worked to add new applications, like streaming video, subscription bundles, and augmented reality. The firm designs its own software and semiconductors while working with subcontractors like Foxconn and TSMC to build its products and chips. Slightly less than half of Apple's sales come directly through its flagship stores, with a majority of sales coming indirectly through partnerships and distribution.
After a thorough review of the options trading surrounding Apple, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Apple</h3>
<ul>
<li>Trading volume stands at 24,595,000, with AAPL's price up by 1.67%, positioned at $231.82.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 86 days.</li>
</ul>
<h3>What The Experts Say On Apple</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $264.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Apple, targeting a price of $275. 
&#x2A; An analyst from Loop Capital has revised its rating downward to Hold, adjusting the price target to $230. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $260. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Apple with a target price of $294. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for Apple, targeting a price of $265. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Apple options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

AAPL

Behind the Scenes of Apple's Latest Options Trends

Investors with a lot of money to spend have taken a bullish stance on Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TSM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 105 uncommon options trades for Taiwan Semiconductor.
This isn't normal.
The overall sentiment of these big-money traders is split between 42% bullish and 40%, bearish.
Out of all of the special options we uncovered, 43 are puts, for a total amount of $4,591,158, and 62 are calls, for a total amount of $8,659,150.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $90.0 and $330.0 for Taiwan Semiconductor, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Taiwan Semiconductor's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Taiwan Semiconductor's significant trades, within a strike price range of $90.0 to $330.0, over the past month.
<h3>Taiwan Semiconductor 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738693828_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$9.95</td>
<td>$9.85</td>
<td>$9.95</td>
<td>$220.00</td>
<td>$1.2M</td>
<td>10.5K</td>
<td>1.3K</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$9.9</td>
<td>$9.85</td>
<td>$9.86</td>
<td>$210.00</td>
<td>$344.7K</td>
<td>10.2K</td>
<td>676</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$47.45</td>
<td>$46.6</td>
<td>$47.0</td>
<td>$180.00</td>
<td>$282.0K</td>
<td>2.8K</td>
<td>106</td>
</tr>
<tr>
<td>TSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$36.4</td>
<td>$35.2</td>
<td>$36.15</td>
<td>$200.00</td>
<td>$180.6K</td>
<td>133</td>
<td>50</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$4.9</td>
<td>$4.8</td>
<td>$4.81</td>
<td>$240.00</td>
<td>$146.1K</td>
<td>2.9K</td>
<td>346</td>
</tr>
</tbody>
</table>

<h3>About Taiwan Semiconductor</h3>
Taiwan Semiconductor Manufacturing Co. is the world's largest dedicated chip foundry, with over 60% market share. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the US in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD, and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs. TSMC employs more than 73,000 people.
Following our analysis of the options activities associated with Taiwan Semiconductor, we pivot to a closer look at the company's own performance.
<h3>Taiwan Semiconductor's Current Market Status</h3>
<ul>
<li>Trading volume stands at 7,951,459, with TSM's price up by 2.15%, positioned at $204.1.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 72 days.</li>
</ul>
<h3>Expert Opinions on Taiwan Semiconductor</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $240.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $225. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Taiwan Semiconductor, which currently sits at a price target of $255. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Taiwan Semiconductor, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Taiwan Semiconductor Unusual Options Activity For February 04

Whales with a lot of money to spend have taken a noticeably bearish stance on Upstart Hldgs.
Looking at options history for Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) we detected 21 trades.
If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 57% with bearish.
From the overall spotted trades, 11 are puts, for a total amount of $700,805 and 10, calls, for a total amount of $611,608.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $52.5 to $100.0 for Upstart Hldgs during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Upstart Hldgs's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Upstart Hldgs's substantial trades, within a strike price spectrum from $52.5 to $100.0 over the preceding 30 days.
<h3>Upstart Hldgs Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738693823_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$8.6</td>
<td>$8.3</td>
<td>$8.4</td>
<td>$70.00</td>
<td>$144.4K</td>
<td align="right">851</td>
<td align="right">578</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$23.8</td>
<td>$23.2</td>
<td>$23.8</td>
<td>$67.50</td>
<td>$142.8K</td>
<td align="right">42</td>
<td align="right">60</td>
</tr>
<tr>
<td>UPST</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/07/25</td>
<td>$6.05</td>
<td>$5.65</td>
<td>$5.85</td>
<td>$60.00</td>
<td>$140.4K</td>
<td align="right">11</td>
<td align="right">241</td>
</tr>
<tr>
<td>UPST</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$4.5</td>
<td>$4.4</td>
<td>$4.5</td>
<td>$52.50</td>
<td>$103.9K</td>
<td align="right">279</td>
<td align="right">232</td>
</tr>
<tr>
<td>UPST</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$17.35</td>
<td>$17.3</td>
<td>$17.35</td>
<td>$79.00</td>
<td>$69.4K</td>
<td align="right">50</td>
<td align="right">40</td>
</tr>
</tbody>
</table>

<h3>About Upstart Hldgs</h3>
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit and small dollar loans.
In light of the recent options history for Upstart Hldgs, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Upstart Hldgs</h3>
<ul>
<li>With a trading volume of 1,485,413, the price of UPST is up by 1.3%, reaching $63.99.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 7 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Upstart Hldgs, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

UPST

Market Whales and Their Recent Bets on UPST Options

Retirement is the time when work takes a backseat, and the focus shifts to enjoying life's quieter moments. You might expect net worth to decline once <a href="https://www.benzinga.com/personal-finance/24/10/41127976/are-you-a-rich-retiree-heres-the-net-worth-and-income-you-need-to-be-in-the-top-10">retirees start dipping into their savings</a>, but here's the twist: for many retirees, net worth doesn't just hold steady—it grows.
Recent data shows a surprising trend. The average retiree's net worth not only remains solid but actually sees a noticeable increase, especially in the early years of retirement.
Retiree Net Worth by the Numbers
For retirees aged 65 to 74, the average net worth is an impressive $1,794,600, while the median net worth sits at $409,900. The gap between these figures highlights the role of wealth inequality—while some retirees have considerable assets, others don't have nearly as much, pulling the median lower.
Don't Miss:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>
As retirees age, the numbers remain striking. For those 75 and older, the average net worth is around $1,624,100, with a median net worth of $335,600. Even as seniors begin drawing from their savings, many still maintain a solid financial cushion.
Why Does Net Worth Grow After Retirement?
The idea of net worth growing during retirement might seem counterintuitive, but several factors contribute to this trend:
<ul>
<li>Reduced Expenses: <a href="https://www.benzinga.com/personal-finance/24/07/39866450/the-average-retiree-spends-over-52-000-a-year-and-75-of-that-goes-to-just-five-expenses-how-does">Retirees often spend less</a>, especially on work-related costs like commuting, professional attire, or meals on the go. This reduced spending allows savings and investments to stretch further.</li>
<li>Reliable Income Sources: <a href="https://www.benzinga.com/personal-finance/25/01/42850946/planning-your-retirement-new-changes-to-social-security-in-2025-could-affect-you">Social Security and pensions</a> provide steady income, while many retirees benefit from appreciating assets, such as home values and investments.</li>
<li>Healthcare Costs Stabilize: Medicare kicks in at 65, easing the financial burden of healthcare for many retirees, though individual costs may still vary.</li>
</ul>
These factors combined help retirees grow or maintain their wealth, even as they transition into their post-work years.
Trending: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
The Wealth Gap: Gender Differences in Retirement
While average figures paint a rosy picture, not everyone's retirement story looks the same. A glaring wealth gap persists, particularly between men and women. Here are some statistics from the U.S. Department of Labor:
<ul>
<li>Women aged 50 and older have about $0.77 in wealth for every dollar held by men.</li>
<li>The median retirement savings for women is $43,000, less than half of men's $91,000.</li>
<li>Only 22% of women have saved $100,000 or more for retirement, compared with 30% of men.</li>
<li>Meanwhile, 25% of women report saving less than $10,000—or nothing at all—compared with 16% of men.</li>
</ul>
Trending: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
Key Takeaways for Retirees
The disparity in net worth shows the importance of financial planning, especially as retirement nears. For retirees who plan carefully, there's a strong chance of maintaining or even growing their net worth, thanks to a mix of lower expenses, stable income, and strategic investing.
At the same time, gaps in wealth and savings point to the need for better retirement strategies, particularly for women, who tend to face unique financial challenges. Addressing these gaps could help ensure a more secure and equitable retirement for everyone.
See Also: <a href="https://www.benzinga.com/money/suze-orman-retirement-bucket">&#8216;Which Bucket Do I Draw From First?&#8217; Suze Orman Explains To 67-Year-Old The Best Order For Tapping Into Her Retirement Accounts</a>
Planning for a Secure and Rewarding Retirement
Retirement isn't just the end of a career—it's a chance to watch your hard work and financial discipline come to life. Whether you're just starting to save or you're already looking ahead to life after work, these trends show that a stable, even growing, net worth is possible with the right approach.
<a href="https://www.benzinga.com/money/are-you-rich">Consulting a financial advisor</a> can make a big difference, helping you tailor a plan that fits your goals and ensures you're making the most of your resources.
Retirement doesn't have to mean cutting back—it can mean thriving. With the right guidance and effort, those golden years can shine brighter than you'd ever imagined.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>

Personal Finance

Can You Guess The Average Retiree's Net Worth? Surprisingly, It Tends To Skyrocket During Retirement

SNOW

UPDATE: Article "Snowflake In Talks To Acquire Analytics Startup Redpanda", Was Reported January 29, 2025

U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the <a href="https://www.benzinga.com/news/econ-s">world&#8217;s two largest economies.</a>
China responded to President Donald Trump&#8216;s 10% import tariff with targeted countermeasures, including restrictions on key mineral exports to the U.S. and tariffs on American energy products.
Beijing is raising tariffs by 10%-15% on select U.S. imports, including coal, liquefied natural gas, crude oil, agricultural machinery and vehicles. Additionally, China added PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) and Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) to its &#8220;Unreliable Entity List,&#8221; citing the need to &#8220;safeguard national sovereignty, security, and development interests,&#8221; and opened an antitrust investigation on Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>).
Market participants had anticipated a call between Trump and Chinese President Xi Jinping on Tuesday, but media reports indicated the conversation would not happen today.
The trade developments had an immediate impact on oil markets, with West Texas Intermediate crude futures plunging 3% overnight to as low as $70 per barrel. 
Yet, prices rebounded sharply Tuesday morning following reports that Trump is considering issuing a memorandum aimed at inflicting <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43469234/trump-prepares-maximum-pressure-on-iran-oil-jumps-above-73-energy-stocks-rally">maximum economic damage on Iran</a>, potentially leading to a sharp decline in Iranian oil production.
Energy stocks outperformed on the day, while utilities lagged. 
Among individual stocks, Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) rocketed 22% after posting strong earnings and a revenue beat. 
In the commodities market, gold added more than 1%, extending its all-time high, and silver jumped 2.2%. Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) declined 2% to $99,000.
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,281.54</td>
<td>1.0%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,495.31</td>
<td>0.9%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,029.97</td>
<td>0.6%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,501.00</td>
<td>0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:55 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;rose 0.5% to $600.53.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) inched 0.1% higher to $444.77.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.9% to $522.81.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 1.1% to $226.80.</li>
<li>The&nbsp;Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 1.9%; the&nbsp;Utilities Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 0.8%.</li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
Stocks reacting to earnings report included: 
<ul>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>): down 1.53%</li>
<li>PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>): down 4.43%</li>
<li>Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>): down 10.49%</li>
<li>PayPal Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>): down 11.57%</li>
<li>Archer-Daniels-Midland Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>): down 3.58%</li>
<li>KKR &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>): down 7.90%</li>
<li>Cummins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>): up 3.81%</li>
<li>Enterprise Products Partners L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>): down 0.99%</li>
<li>Marathon Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>): up 5.85%</li>
<li>Estee Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>): down 16.35%</li>
<li>Apollo Global Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>): down 2.78%</li>
<li>Fox Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>): up 4.00%</li>
<li>Ametek Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>): down 1.00%</li>
<li>Xylem Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>): up 5.85%</li>
<li>Ferrari NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>): up 7.62%</li>
<li>Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>): up 10.46%</li>
<li>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>): up 4.71%</li>
<li>Jacobs Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>): down 2.72%</li>
<li>Aramark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>): down 1.51%</li>
<li>Gartner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>): up 0.77%</li>
<li>Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>): down 3.41%</li>
<li>Atkore Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>): down 20.50%</li>
<li>Berry Global Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>): up 4.15%</li>
<li>WEC Energy Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>): down 1.52%</li>
<li>Hubbell Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>): down 0.55%</li>
<li>TransDigm Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>): down 1.60%</li>
<li>Graphic Packaging Holding Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>): down 1.76%</li>
<li>CNH Industrial NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNHI#NYSE">CNHI</a>): up 1.71%</li>
<li>Ingredion Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGR#NYSE">INGR</a>): down 6.12%</li>
<li>ATI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>): up 7.02%</li>
<li>Ball Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>): down 8.03%</li>
<li>Lancaster Colony Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LANC#NASDAQ">LANC</a>): up 9.27%</li>
<li>Premier Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>): down 15.36%</li>
<li>MPLX LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>): up 2.92%</li>
<li>Oaktree Specialty Lending Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCSL#NASDAQ">OCSL</a>): down 3.42%</li>
<li>PJT Partners Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJT#NYSE">PJT</a>): up 12.77%</li>
<li>Energizer Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENR#NYSE">ENR</a>): down 4.45%</li>
<li>Silicon Laboratories Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>): down 1.05%</li>
<li>Hamilton Lane Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>): down 0.01%</li>
<li>Madison Square Garden Sports Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSGS#NYSE">MSGS</a>): down 3.74%</li>
<li>Pentair Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>): down 1.89%</li>
<li>Amcor Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMCR#NYSE">AMCR</a>): up 3.87%</li>
<li>Inmode Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>): up 2.82%</li>
<li>Willis Towers Watson Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>): down 3.54%</li>
<li>Axalta Coating Systems Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>): up 7.86%</li>
<li>Mesa Laboratories Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>): up 10.48%</li>
</ul>
Major companies reporting their earnings after the close are Alphabet Inc., Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Mondelez International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>), Chipotle Mexican Grill Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>), Prudential Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>), Simon Property Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>), Atmos Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATO#NYSE">ATO</a>), Aspen Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZPN#NASDAQ">AZPN</a>), Carlisle Cos. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>), Fair Isaac Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>), Jack Henry &amp; Associates Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>), Idex Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEX#NYSE">IEX</a>) and Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>).
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43468887/robert-f-kennedy-nomination-advances-to-full-senate-vaccine-stocks-drop">Robert F. Kennedy&#8217;s Health Secretary Nomination Advances To Full Senate: Vaccine Stocks Drop</a></li>
</ul>
Photo: Marek Masik via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Macro Economic Events

Commodities

Global

Econ #s

Economics

Tech

$BTC

AMCR

AMGN

ARMK

ATKR

AXTA

AZPN

BALL

BERY

CNHI

SPDR Dow Jones Industrial Average ETF Trust

ENPH

FICO

FOXA

GOOG

GOOGL

HLNE

HUBB

ILMN

INGR

INMD

JKHY

LANC

MDLZ

MLAB

MPLX

MSGS

OCSL

PINC

PLTR

PYPL

RACE

REGN

SLAB

SPOT

US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday?

HSBC analyst Edoardo Spina upgrades Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) from Hold to Buy and raises the price target from $63 to $77.

Upgrades

APTV

HSBC Upgrades Aptiv to Buy, Raises Price Target to $77

<a href="https://www.theinformation.com/articles/eyeing-higher-margins-aws-and-other-cloud-providers-embrace-deepseek" title="https://www.theinformation.com/articles/eyeing-higher-margins-aws-and-other-cloud-providers-embrace-deepseek">https://www.theinformation.com/articles/eyeing-higher-margins-aws-and-other-cloud-providers-embrace-deepseek</a>

AMZN

'Eyeing Higher Margins, AWS And Other Cloud Providers Embrace DeepSeek' - The Information

Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) reported better-than-expected second-quarter financial results <a href="https://www.benzinga.com/quote/CLX/earnings">Monday after the bell</a>.
Clorox reported fiscal second-quarter revenue of $1.69 billion, beating the consensus estimate of $1.63 billion, according to Benzinga Pro. The household consumer products company reported adjusted earnings of $1.55 per share, beating analyst estimates of $1.41 per share.
"We achieved better-than-expected results across sales, margin and EPS in the second quarter due to our strong demand creation plans, which also supported our share growth," said Linda Rendle, chair and CEO of Clorox. "We are further advancing our transformation as we embark upon a significant milestone with our Enterprise Resource Planning transition in the U.S., resulting in our updated outlook. I am confident that we are taking the right actions to deliver strong financial performance and long-term, profitable growth."
Clorox raised its full-year earnings forecast from a range of $6.65 to $6.90 per share to a new range of $6.95 to $7.35 per share versus estimates of $6.84 per share. The company also guided for 2025 net sales in a range of down 1% to up 2%.
Clorox shares fell 6.6% to trade at $149.19 on Tuesday.
These analysts made changes to their price targets on Clorox following earnings announcement.
<ul>
<li>Wells Fargo analyst Chris Carey maintained Clorox with an Equal-Weight and raised the price target from $157 to $161.</li>
<li>JP Morgan analyst Andrea Teixeira maintained Clorox with a Neutral and raised the price target from $171 to $173.</li>
</ul>
Considering buying CLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04132432/image-28-1024x574.png" alt="" class="wp-image-765442" style="width:513px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04132432/image-28-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04132432/image-28-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04132432/image-28-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04132432/image-28.png 1116w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43463896/mcdonalds-to-290-here-are-10-top-analyst-forecasts-for-tuesday">McDonald&#8217;s To $290? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Clorox Analysts Boost Their Forecasts Following Upbeat Earnings

Nintendo Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>) reported <a target="_blank" href="https://www.benzinga.com/topic/nintendo-switch" rel="noreferrer noopener">third-quarter revenue</a> of $1.10 billion (432.92 billion Japanese yen), down from $1.70 billion (598.56 billion Japanese yen) a year ago.
EPS of 110.40 Japanese yen compared to 117.45 Japanese yen <a target="_blank" href="https://www.nintendo.co.jp/ir/en/events/index.html" rel="noreferrer noopener">a year ago</a>.
Nintendo sold 4.82 million Nintendo Switch hardware in the third quarter, bringing the total for the current fiscal year to 9.54 million units (down by 30.6% Y/Y).
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42161830/sony-eyes-portable-gaming-market-with-new-handheld-console-in-development" rel="noreferrer noopener">Sony Eyes Portable Gaming Market With New Handheld Console In Development</a>
The company expects to sell 11.00 million units of Nintendo Switch hardware in fiscal 2025, down from 12.50 million units it previously expected. It expects to sell 150 million units of Nintendo Switch software in fiscal 2025, down from 160 million units it previously expected.
The company expects fiscal 2025 net sales of 1.19 trillion Japanese yen (prior 1.28 trillion Japanese yen) and EPS of 231.91 Japanese yen (prior 257.68 Japanese yen).
Nintendo reduced the annual dividend forecast to 116 Japanese yen per share from 129 Japanese yen per share.
In January, <a target="_blank" href="https://www.benzinga.com/general/gaming/25/01/43051841/nintendo-shares-drop-5-on-tokyo-exchange-after-switch-2-announcement" rel="noreferrer noopener">Nintendo shared plans</a> to showcase the new console at Nintendo Switch, which will start in April. However, the company also flagged that Nintendo Switch games may not be supported or fully compatible with the Switch 2. Nintendo Switch has sold over 125 million units since its 2017 debut.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/42954938/pubg-developer-krafton-invests-136-million-in-game-studios-expands-ai-team-for-future-gaming-innovations" target="_blank" rel="noreferrer noopener">PUBG Developer Krafton Invests $136 Million in Game Studios, Expands AI Team for Future Gaming Innovations</a></li>
</ul>
Photo via Shutterstock

Guidance

Dividends

NTDOY

Nintendo Q3 Revenue Drops, Cuts Outlook and Dividend, Switch Sales Slow Ahead of Next-Gen Console

JMP Securities analyst Trevor Walsh maintains Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) with a Market Outperform and raises the price target from $610 to $725.

AXON

JMP Securities Maintains Market Outperform on Axon Enterprise, Raises Price Target to $725

<a href="https://blogs.nvidia.com/blog/blackwell-coreweave-gb200-nvl72-instances-cloud/#:~:text=CoreWeave%20launches%20the%20first%20NVIDIA,next%20era%20of%20AI%20reasoning.&amp;text=AI%20reasoning%20models%20and%20agents,massive%20compute%20and%20optimized%20software" title="https://blogs.nvidia.com/blog/blackwell-coreweave-gb200-nvl72-instances-cloud/#:~:text=CoreWeave%20launches%20the%20first%20NVIDIA,next%20era%20of%20AI%20reasoning.&amp;text=AI%20reasoning%20models%20and%20agents,massive%20compute%20and%20optimized%20software">https://blogs.nvidia.com/blog/blackwell-coreweave-gb200-nvl72-instances-cloud/#:~:text=CoreWeave%20launches%20the%20first%20NVIDIA,next%20era%20of%20AI%20reasoning.&amp;text=AI%20reasoning%20models%20and%20agents,massive%20compute%20and%20optimized%20software</a>.

NVDA

"NVIDIA Blackwell Now Generally Available In The Cloud; CoreWeave launches the first NVIDIA GB200 NVL72-cloud based instances to power the next era of AI reasoning"

Triumph Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGI#NYSE">TGI</a>) reached a definitive acquisition agreement with private equity firms, <a href="https://www.benzinga.com/quote/TGI">Warburg Pincus and Berkshire Partners.</a>
Valued at roughly $3 billion, the transaction will result in Triumph becoming a privately owned entity which will be jointly managed by Warburg Pincus and Berkshire Partners.
TRIUMPH&nbsp; shareholders will receive $26.00 per share in cash, representing a premium of about 123% to the unaffected closing stock price of $11.65 per share as of the close on October 9, 2024, the last full trading day before media reports regarding a possible sale transaction. The deal price represents a premium of over 38% to the last closing price of $18.74 on January 31, 2025.
"Over the last few years, TRIUMPH successfully optimized our portfolio, built around a world class team and capabilities. This transaction recognizes our Company's position as a valued provider of mission-critical engineered systems and proprietary components for both OEM and aftermarket customers," said Chairman, President and CEO, Dan Crowley.
Triumph Group shares gained 0.1% to trade at $25.08 on Tuesday.
These analysts made changes to their price targets on Triumph Group following the announcement.
<ul>
<li>Baird analyst Peter Arment downgraded Triumph Group from Outperform to Neutral and raised the price target from $20 to $26.</li>
<li>Truist Securities analyst Michael Ciarmoli maintained Triumph Group with a Hold and raised the price target from $19 to $26.</li>
</ul>
Considering buying TGI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04131620/image-27-1024x576.png" alt="" class="wp-image-765417" style="width:559px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04131620/image-27-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04131620/image-27-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04131620/image-27-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04131620/image-27.png 1087w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43463896/mcdonalds-to-290-here-are-10-top-analyst-forecasts-for-tuesday">McDonald&#8217;s To $290? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

These Analysts Cut Their Forecasts On Triumph Group

JMP Securities analyst Trevor Walsh maintains Kratos Defense &amp; Security (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) with a Market Outperform and raises the price target from $30 to $40.

KTOS

JMP Securities Maintains Market Outperform on Kratos Defense & Security, Raises Price Target to $40

S&amp;P Global's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) short percent of float has fallen 10.0% since its last report. The company recently reported that it has 2.53 million shares sold short, which is 0.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.78 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>S&amp;P Global Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738692922_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for S&amp;P Global has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing S&amp;P Global's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, S&amp;P Global's peer group average for short interest as a percentage of float is 3.28%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

SPGI

How Is The Market Feeling About S&P Global?

BREA, MSAI and APM among pre-market losers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Creative Medical Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/celz-stock-quote/">CELZ</a>) just reported results for the first quarter of 2024.<ul><li>Creative Medical Tech reported earnings per share of -73 cents. This was above the analyst estimate for EPS of -$1.15.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/celz-stock-earnings-creative-medical-tech-for-q1-of-2024/">CELZ Stock Earnings: Creative Medical Tech Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CELZ Stock Earnings: Creative Medical Tech Beats EPS for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Creative Medical Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/celz-stock-quote/">CELZ</a>) just reported results for the second quarter of 2024.<ul><li>Creative Medical Tech reported earnings per share of -$1.11. This was below the analyst estimate for EPS of -84 cents.</li><li>The company reported revenue of $8,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/celz-stock-earnings-creative-medical-tech-for-q2-of-2024/">CELZ Stock Earnings: Creative Medical Tech Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CELZ Stock Earnings: Creative Medical Tech Misses EPS for Q2 2024

Creative Medical Technology files for $50M mixed securities shelf

It seems time for the Securities and Exchange Commission to oversee stock advertising and consider a ban, or at least a danger warning label.

Are Pharma Stocks Harmful To Your Financial Health ?

Creative Medical Technology (CELZ) Holdings has entered into definitive securities purchase agreements with certain institutional investors for the...

Creative Medical to sell 418,552 shares at $4.42 in registered direct offering

16:08 EST Creative Medical Technology (CELZ) files to sell 837,104 shares of common for holders Published first on TheFly – the ultimate source for...

Creative Medical Technology files to sell 837,104 shares of common for holders

Creative Medical Technology files to sell 0.83M shares of common stocks by selling shareholders

Creative Medical Technology (CELZ) announces the successful completion of an independent interim safety review by the Data Safety Monitoring Board,...

Creative Medical advances FDA cleared ADAPT trial with independent review

Creative Medical Technology (CELZ) announced initial data from the first cohort of its ongoing Phase 1/2 clinical trial of CELZ-201-DDT, the Compan...

Creative Medical reports data from first cohort in Phase 1/2 CELZ-201-DDT trial

APVO

AVGR

BIAF

BREA

CELZ

GROM

IFBD

IMRN

MAXN

MBIO

MSAI

NTRB

Biotech Finds Mid-Week Success Following FDA Announcement

Press Releases

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access

Market Momentum: NASDAQ SmallCaps Sparking Waves in March 2024: CELZ, DYAI, GROM, VTAK, BREA

Creative Medical Technology Holdings Provides Corporate Update

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program

Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

Comments

Creative Medical Tech

Interés en corto

Creative Medical Tech (NASDAQ:CELZ) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL